Abstract: An apparatus and method for an examination apparatus that includes a manually movable structure having a first movement from a free state to a compressed state and a second reversing movement from the compressed state to the free state. Also included is a plurality of fingers that are disposed adjacent to the structure. The fingers having a stowed state and an open state, the stowed state having a nested relationship between the fingers to reduce a silhouette profile size. In moving from the stowed state to the open state of the plurality of fingers requires a selected sequential movement of each the fingers to proceed from the nested relationship to the open state that is accommodated by an assemblage for moving the fingers sequentially utilizing the manually operated structure, wherein the fingers are moved from the stowed state to the open state and reversed manually.

Abstract: An apparatus and method for an examination apparatus that includes a manually movable structure having a first movement from a free state to a compressed state and a second reversing movement from the compressed state to the free state. Also included is a plurality of fingers that are disposed adjacent to the structure. The fingers having a stowed state and an open state, the stowed state having a nested relationship between the fingers to reduce a silhouette profile size. In moving from the stowed state to the open state of the plurality of fingers requires a selected sequential movement of each the fingers to proceed from the nested relationship to the open state that is accommodated by an assemblage for moving the fingers sequentially utilizing the manually operated structure, wherein the fingers are moved from the stowed state to the open state and reversed manually.

Abstract: A method of diagnosing the presence or predicting the course of breast cancer by measuring the expression of a combination of Marker genes comprising a tissue-specific gene and a non-tissue specific gene in a cell or tissue sample derived from a patient. In one aspect of the invention, the genes are mammaglobin and CK19. Kits, nucleic acid primers and probes and controls are provided.

Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.

Abstract: DNA isolates coding for the lymphocyte homing receptor and methods of obtaining such DNA are provided, together with expression systems for recombinant production of the lymphocyte homing receptor useful in therapeutic or diagnostic compositions.

Abstract: Novel glycosylsulfotransferases (GST-4?, GST-4?, and GST-6) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-4?, GST-4?, and GST-6.

Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.

Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.

Abstract: The present invention provides methods of treating traumatic spinal cord injury, methods of reducing cell-mediated demyelination of long descending fiber tracts or local circuits in the spinal cord following traumatic spinal cord injury, and methods for improving or restoring locomotor recovery and/or fine motor movement in an individual following spinal cord injury. The present invention further provides compositions for use in the methods. The methods generally involve administering to an individual in need thereof an effective amount of an L-selectin antagonist.

Abstract: Podocalyxin like proteins (e.g. PCLP and PCLP-2) having selectin ligand activity are provided. Also provided are nucleic acid compositions encoding novel PCLP-2 proteins. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment therapies for disease conditions associated with podocalyxin like protein activity. In particular, methods of treating diseases associated with podocalyxin like protein selectin binding activity and/or chemokine presenting activity are provided, where such diseases include inflammation and the like.

Abstract: Topical methods and compositions are disclosed for the treatment of pseudofolliculitis barbae and ingrown hair. The compositions comprise acetylsalicylic acid, propylene glycol, glycerine, and isopropyl alcohol. The method involves the step of applying the composition to the beard areas of the face after shaving. The acetylsalicylic acid is dissolved in a solvent mixture comprising propylene glycol, glycerine, and isopropyl alcohol. The acetylsalicylic acid is present in the range of between about 5 percent by weight per unit volume of the solvent mixture up to saturation of the solvent mixture. The solvent mixture comprises propylene glycol in the range of about 5 percent to 15 percent by volume, glycerine in the range of about 1 percent to 10 percent by volume, and the balance of the volume made up with isopropyl alcohol alone or a solution comprising at least 50 percent by volume of isopropyl alcohol.

Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.

Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.

Abstract: The present invention provides novel assays for determining the ability of a test compound to inhibit intercellular adhesion mediated by a selectin receptor, such as the LHR. The assays involve contacting the test compound with the receptor and an isolated receptor-binding agent. The receptor-binding agent is a sulfated polysaccharide, a sulfated glycolipid, or a compound comprising the extracellular region of an endothelial cell surface glycoprotein. Also provided are compositions comprising a compound comprising the extracellular region of an endothelial cell surface protein, which is specifically recognized by lymphocyte homing receptors.

Abstract: The present invention provides pharmaceutical compositions and methods for treating demyelinating diseases. The compositions comprise a blocking agent which inhibits LHR-mediated binding of leukocytes to myelin.